We would like to express sincere gratitude to all of our investors and shareholders for their continued support and understanding in the ways that we choose to do business. It has long been our ambition to grow our business in Europe and we are immensely proud to have realised that goal.

Our industry is facing fierce competition as pharmaceutical companies aggressively expand and, combined with cost saving measures within the healthcare space imposed by governments in most developed countries, the business environment has become increasingly challenging.

Despite this, our mission remains to put patients at the heart of everything we do.

We aim to achieve this with a strong presence in Europe, which conducts business operations recognised by patients, their families, healthcare providers and broader communities. We are committed to the research and development of innovative drugs in areas of unmet medical need and supplying the best possible medicines to protect the health and wellbeing of the patients we serve.

We believe that the implementation of this aim will not only benefit patients, but also all of our stakeholders, including shareholders and investors. For further information about Investor Relations at Shionogi please click here.

Thank you.

John Keller, Ph.D., Senior Executive Officer, Senior Vice President, Global Business Division of Shionogi & Co., Ltd.

Isao Teshirogi, Ph.D, President and CEO, Shionogi & Co., Ltd., Japan

Shionogi B.V. is a private limited liability company formed under Dutch law. We are registered with the Trade Register of the Dutch Chamber of Commerce under number 73229180 and our registered address is Kingsfordweg 151, 1043GR, Amsterdam, the Netherlands. Our VAT number is NL859411011B01. We have a UK establishment registered with Companies House under number BR020960, and its registered address is at 33 Kingsway, London, WC2B 6UF.

NP-EU-NP-0169 | August 2022